A key role for orexin in panic anxiety. by Johnson, Philip L et al.
UCSF
UC San Francisco Previously Published Works
Title
A key role for orexin in panic anxiety.
Permalink
https://escholarship.org/uc/item/00x1k8w8
Journal
Nature medicine, 16(1)
ISSN
1078-8956
Authors
Johnson, Philip L
Truitt, William
Fitz, Stephanie D
et al.
Publication Date
2010
DOI
10.1038/nm.2075
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
A KEY ROLE FOR OREXIN IN PANIC ANXIETY
Philip L. Johnson1,*, William Truitt1,2,*, Stephanie D. Fitz1, Pamela E. Minick1, Amy 
Dietrich1, Sonal Sanghani3, Lil Träskman-Bendz4, Andrew W. Goddard1, Lena Brundin4, 
and Anantha Shekhar1,5
1Department of Psychiatry, Indiana University School of Medicine, Indianapolis, IN 46202, U.S.A.
2Department of Anatomy and Cell Biology, Indiana University School of Medicine, Indianapolis, IN 
46202, U.S.A.
3Department of Biochemistry, Indiana University School of Medicine, Indianapolis, IN 46202, 
U.S.A.
4Section of Psychiatry, Department of Clinical Sciences, Lund University Hospital, 221 85 Lund, 
Sweden
5Indiana Clinical and Translational Sciences Institute Indianapolis, IN 46202, USA
Introductory paragraph
Panic disorder is a severe anxiety disorder with recurrent, debilitating panic attacks. In subjects 
with panic disorder there is evidence of decreased central GABAergic activity as well as marked 
increases in autonomic and respiratory responses following intravenous infusions of 0.5M sodium 
lactate1–3. In an animal model of panic disorder, chronic inhibition of GABA synthesis in the 
dorsomedial/perifornical hypothalamus of rats produces anxiety-like states and a similar 
vulnerability to sodium lactate-induced cardioexcitatory responses4–9. The dorsomedial/
perifornical hypothalamus is enriched in orexin (ORX, also known as hypocretin)-containing 
neurons10 that play a critical role in arousal10,11, vigilance10 and central autonomic 
mobilization12, all of which are key components of panic. Here, we demonstrate that activation of 
the ORX neurons is necessary for developing a panic-prone state in the animal model, and either 
silencing the hypothalamic ORX gene (Hcrt) product with RNA interference or systemic ORX1 
antagonists blocks the panic responses. Moreover, we show that subjects with panic anxiety have 
elevated levels of ORX in the cerebrospinal fluid compared to subjects without panic anxiety. 
Taken together our results suggest that the ORX system may be involved in the pathophysiology 
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of panic anxiety, and that ORX antagonists constitute a potential novel treatment strategy for panic 
disorder.
Body
Panic disorder is characterized by recurrent episodes of severe anxiety accompanied by 
multiple physical symptoms such as increased cardiorespiratory responses13, and constitutes 
a risk factor for suicidal behavior3. Panic attacks characterized by sudden onset of fear along 
with rapid increases in respiration and heart rates16 can reliably be induced in panic disorder 
subjects by specific and normally innocuous interoceptive stimuli (e.g., intravenous 0.5M 
sodium lactate or yohimbine14–16, or 7% CO2 inhalations17). This suggests that global 
neural pathways which modulate arousal are perturbed in these subjects. Consistent with 
this, reduced central GABAergic activity has been reported in subjects with panic disorder1 
and drugs that restore GABAergic inhibition (e.g. benzodiazepines) are clinically effective 
treatments2. In rats, acute disruption of GABAergic inhibition in panic-generating CNS sites 
such as the dorsomedial/perifornical hypothalamus, amygdala or the dorsal periaqueductal 
grey leads to panic-like behavior and increased cardiorespiratory responses18. Furthermore, 
after chronically inhibiting GABA synthesis in the dorsomedial/perifornical hypothalamus 
of rats [with 5 days of local l-allylglycine (l-AG): a GABA synthesis inhibitor infusions 
using osmotic minipumps connected to a cannula], sodium lactate challenges produce 
anxiety [measured by social interaction, elevated plus maze, open field test and freezing in 
defensive probe burying test] as well as panic [defined as increased “flight”-like locomotion 
and increased heart rate (HR), mean arterial pressure responses (MAP)]4–9. This is also 
pharmacologically validated with anti-panic drugs such as alprazolam8, and provides a 
robust rat model of human sodium lactate-induced panic attacks.
Coincidentally, ORX producing neurons are exclusive to the dorsomedial/perifornical and 
lateral hypothalamus10,19 and are known to regulate feeding, wakefulness10,11 and 
vigilance10. The ORX neurons are also involved in mobilizing sympathetic responses and 
desensitizing the parasympathetically mediated baroreflex12 to permit simultaneous 
increases of blood pressure and heart rate5, which are all key components of panic. 
Autonomic nervous system targets of ORX neurons are also activated by sodium lactate 
infusions in the above described `sodium lactate panic prone rats' but not in controls5. 
Finally, mice lacking the Hcrt gene have attenuated defence responses to panic cues and 
cardioexcitatory responses following disinhibition of the dorsomedial/perifornical 
hypothalamus20. Based on these data we hypothesised that the ORX system plays a critical 
role in producing panic attacks.
Utilizing our established panic model4–9 (also see supplemental materials), we first 
observed that ORX-positive cells (specifically those in the dorsomedial/perifornical 
hypothalamus) are selectively (Suppl. Fig. 1) activated (i.e., increased c-Fos) following 
sodium lactate administration in panic-prone rats (p=0.001, Fig. 1a), and this activation 
correlated with increase in anxiety-related behavior (Fig. 1a).
We then demonstrated that sodium lactate-induced panic responses are dependent on 
translation of the Hcrt gene that produces preproOrexin mRNA, by injecting small 
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interfering (si) RNA targeting the preproORX mRNA (siORX) (OnTargetPlus SmartPool® 
Dharmacon) into the dorsomedial/perifornical hypothalamus of panic-prone rats 48 h prior 
to sodium lactate or saline challenges. We used quantitative RT-PCR to assess mRNA levels 
in the combined dorsomedial and lateral hypothalamus. Importantly, injecting panic-prone 
rats with siORX attenuated multiple components of the sodium lactate-induced panic-like 
responses [anxiety-like behavior (siRNA x time effect, p=0.035, Fig. 1b), and 
cardioexcitatory effects (siRNA x time effects for HR, p=0.002; and MAP, p=0.003, Fig. 1d–
e)], whereas si control (siCON) rats displayed the predicted panic-like responses (Fig. 1b–e). 
As expected, treatment with siORX dramatically reduced local preproORX mRNA in 
control (p=0.047, Fig. 1g) and panic-prone rats compared to treatment with siCON, 
(p=0.025, Fig. 1h, also Fig. 1k, Suppl. Table 1). The effect was selective, as neither pro-
dynorphin mRNA (a gene co-expressed in ORX neurons21; p=0.184, Fig. 1i) nor local pro-
opiomelanocortin mRNA (p=0.207, Fig 1j) was reduced by siORX injection. Interestingly, 
once a panic-like response occurred, both preproORX (p=0.007, Fig. 1g) and pro-dynorphin 
(p=0.001, Fig. 1i) mRNA levels were rapidly suppressed, suggesting panic-induced negative 
feedback.
In the next step, we show that sodium lactate-induced panic in panic-prone rats is attenuated 
by systemic pre-treatment with ORX1 receptor antagonists. The selective ORX1 receptor 
antagonist (SB334867, 30 mg/kg, Tocris22) attenuated the anxiety-like behavior [measured 
with social interaction (p=0.001, Fig. 2a) and open field tests (0.025, Fig. 2b)]. This ORX1 
receptor antagonist also blocked the increases in locomotion (p=0.017, Fig. 2a), heart rate 
(p=0.001, Fig. 2a) and blood pressure (p=0.001, Fig. 2a; p=0.001, Fig. 2b) responses 
induced by the sodium lactate challenge. These effects mimicked the effects of pre-treating 
panic-prone rats with alprazolam [3 mg/kg, Sigma (Fig. 2a)], a clinically effective 
benzodiazepine that blocks both spontaneous and sodium lactate-induced panic attacks in 
subjects with panic disorder14,15. Similarly, a second ORX1 receptor antagonist (SB408124, 
30 mg/kg, Tocris) also attenuated the sodium lactate-induced increases in locomotor activity 
(p=0.004, Fig. 2c) and tachycardia responses (p=0.001, Fig. 2c) in another group of panic-
prone rats (See Suppl. Fig. 2a–c for localization of infusion sites). The SB334867 ORX1 
antagonist did not alter anxiety or cardiovascular responses in control rats (n=7/group, 
Suppl. Fig 3), or baseline measures (see Suppl. Results) in panic-prone rats.
One potential concern is that blocking ORX function might induce general somnolence or 
narcoleptic behavior10, thus reducing sodium lactate-induced panic responses. We do not 
believe this to be the case for the following reasons: in a previous study, acute blockade of 
ORX receptors did not result in narcoleptic states11; and reducing ORX activity for short 
periods with either ORX 1 receptor antagonists (Fig. 2a–c) or gene silencing (Fig. 1c) did 
not result in somnolence during testing or alter baseline locomotor activity. In fact, the ORX 
gene silencing or ORX1 receptor antagonist increased social interaction (Fig. 1b, 2a) and 
exploration in the open field (Fig. 2b), clearly arguing against induction of sedation. In 
addition to its attenuation of panic-like responses, the ORX1 receptor antagonist (SB334867, 
30 mg/kg i.p.) also blocks sodium lactate-induced freezing (indicative of panic-like fear) 
observed in the defensive burying test in panic-prone rats (p=0.021, Fig. 3a). Again this is 
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not due to sedative effects of the ORX1 antagonist, since the number of mid-line crossings 
was not reduced in the treated panic-prone rats (Fig. 3b).
The sodium lactate-induced anxiety, but not the cardiorespiratory components of the panic 
response appears to be pivotally linked to the bed nucleus of the stria terminalis23 (Suppl. 
Fig. 5 for hypothetical mapping of implicated neural pathways). Therefore, to confirm an 
end target effect of activating ORX neurons, we focused on the bed nucleus of stria 
terminalis which receives ORX projections from the dorsomedial/perifornical hypothalamus 
[see Sakurai et al., 2007 review]. We injected an ORX1 receptor antagonist (SB334867) 
ipsilaterally into the bed nucleus of the stria terminalis of panic-prone rats, prior to the 
sodium lactate challenge, which reduced anxiety-like behavior compared to the vehicle-
injected rats (p=0.0002, Fig. 3c, Suppl. Fig. 2d).
The animal model of panic disorder utilized here was established over the last 10 years and 
has robust face, predictive and construct validity4–9. The model's predictive validity is 
demonstrated by responses, similar to those observed in subjects with panic disorder, to both 
panic-inducing agents (e.g. sodium lactate, yohimbine, and inhalations of CO2) and anti-
panic effects of therapeutic agents such as alprazolam and group II metabotropic glutamate 
agonists8. Also, this animal model was recently used in a series of preclinical studies to 
identify a novel class of translocator protein agonist (that enhances the central inhibitory 
effects of GABA), which subsequently showed anti-panic properties in clinical trials, further 
strengthening the model's predictive validity24. The construct validity of this model is 
supported by the fact that neural circuits of the dorsomedial/perifornical hypothalamus 
regulate behavioral and autonomic components of the “fight or flight” response in rats25, 
and are implicated in eliciting panic-like responses in humans26 and animals23. Furthermore, 
panic disorder subjects have reported deficits in central GABA activity1 and 
pharmacological restoration of central GABA activity prevents panic attacks2, in accordance 
with our animal model. Also, the panic- and anxiety-like responses noted in this model are 
not likely due to a general increase in arousal, as there are no changes in baseline acoustic 
startle responses (Suppl. Fig. 4). Similarly, there is no increase in baseline startle response in 
human subjects with panic disorder27,28.
In order to clinically validate the role of ORX in panic disorder, cerebrospinal fluid (CSF) 
samples were collected from 53 medication-free subjects who presented with suicidal 
behavior. The subjects were assessed for present symptoms of panic anxiety [as measured 
by the comprehensive neuropsychopathological rating scale (CPRS)] and CSF samples were 
assayed for ORX levels. Increased CSF ORX was observed in subjects with panic anxiety 
compared to subjects without panic anxiety. Furthermore, subjects with only panic anxiety 
had significantly higher CSF ORX than subjects with panic anxiety and co-morbid major 
depressive disorder (p=0.004, Fig. 4, Suppl. Table 2). Our findings of increased ORX in 
subjects with panic anxiety are consistent with a previous report that chronic treatment with 
sertraline, a well known anti-panic and antidepressant drug, reduces ORX levels in the CSF 
whereas bupropion, an antidepressant with a lower efficacy in treating panic disorder, does 
not29.
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Taken together, our translational experiments in animal models and subjects suggest that 
aberrant functioning of the ORX system may underlie panic-attacks. We suggest that ORX1 
receptor antagonists may provide a novel therapeutic approach for the treatment of panic 
disorder.
Methods and Materials
Animals and housing conditions
All experiments used adult male Sprague-Dawley rats (300–350 g, Harlan Laboratories), 
which were individually housed (22 °C; 12/12 light/dark cycle; lights on at 7:00 A.M.) for 
7–10 days prior to surgery. Food and water were provided ad libitum. Animal care 
procedures were conducted in accordance with the NIH Guidelines for the Care and Use of 
Laboratory Animals (NIH Publication no. 80–23) revised 1996 and the guidelines of the 
IUPUI Institutional Animal Care and Use Committee.
Inducing panic-prone state in rats and panic response following sodium lactate (NaLac)
Cannulae (Plastics One Inc.) were directed at the dorsomedial/perifornical hypothalamus 
(DMH/PeF30) and connected to an osmotic minipump (DURECT Corporation) filled with l-
AG solution (a glutamic acid decarboxylase inhibitor) or when applicable d-allylglycine (d-
AG: the inactive isomer of l-AG). Radio-telemetry probes (Data Science International) were 
surgically implanted into the abdomen of rats31 to measure cardiovascular and locomotor 
responses. Rats received intravenous (i.v.) infusions [similar to clinical studies16; 10ml over 
15 min] of either 0.5M NaLac or 0.9% isotonic saline at least five days following the 
initiation of l-AG or d-AG infusions.
c-Fos induction in ORX neurons following infusions of NaLac or saline
l-AG or d-AG treated rats received NaLac or saline challenge (n=6/group for 4 groups) and 
were immediately tested in the social interaction (SI) test. 90 min following the SI test rats 
were perfused and brains were immunoprocessed into 6 parallel sets of coronal section (30 
μm).
Injections of siORX or siCON into the DMH/LH of panic-prone rats
Control rats received stereotaxic injections of OnTargetPlus SmartPool® siRNA against rat 
ppORX mRNA (siORX, 100nMol, Dharmacon) into one side of the DMH/PeF, and negative 
control siRNA (siCON, 100nMol, Dharmacon) into the other side to confirm gene silencing. 
Panic-prone rats were given bilateral siORX or siCON treatment, and 48 hrs later infused 
with saline or NaLac (siCon/Sal n=4, siORX/Sal n=6, siCON/Lac n=5, siORX/Lac n=6). SI 
and cardiovascular responses were recorded and tissue processed for RT-PCR.
Attenuating panic-like responses with systemic ORX1 receptor antagonists
Panic-prone rats received intraperitoneal (i.p.) injections of drug or vehicle 30 min prior to 
i.v. infusions and panic-like responses were assessed. In 1st experiment, rats were injected 
with the ORX1 receptor antagonist SB334867 [30mg/kg, Tocris, in 0.2ml, n=12], 
alprazolam (3mg/kg, Sigma, n=6) or vehicle (0.2ml, n=11) 30 min prior to a NaLac 
Johnson et al. Page 5
Nat Med. Author manuscript; available in PMC 2010 July 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
challenge and the SI test was used to assess anxiety behavior. In 2nd experiment, an open 
field (OF) test was used to assess anxiety [i.p. vehicle+i.v. saline (n=5); i.p. vehicle+i.v. 
NaLac (n=5); or i.p. SB334867 (30mg/kg)+i.v. NaLac (n=6)]. In a final experiment, panic-
prone rats received i.p. injection of an alternative ORX1 receptor antagonist [30mg/kg 
SB408124, Tocris, n=4] or vehicle (0.2ml, n=6) 30 min prior to NaLac.
NaLac effects on unconditioned defensive shock-associated behaviors
Rats were acclimated to the testing apparatus for 10 min with a deactivated shock probe. On 
testing day, panic-prone rats either received an i.p. injection of the ORX1 receptor 
antagonist, SB334867 [30mg/kg, Tocris, n=3], or vehicle (0.2ml, n=6) 30 min prior to the 
i.v. challenge. The SB334867+l-AG group of rats (n=3) and the vehicle+l-AG rats (n=3) 
were given an i.v. infusion of NaLac, whereas the remaining vehicle+l-AG group were 
infused with saline (n=3). Rats were then immediately placed in the test cage with activated 
shock probe (0.7 mA, Lafayette Instruments Co.) for 10 min. Time spent burying; in 
proximity of probe; grooming; freezing; and number of center crossings were assessed32.
ORX1 receptor antagonist into the bed nucleus of the stria terminalis (BNST) of rats
Panic-prone rats (n=5/group in a crossover design) received unilateral injections of 
SB334867 (300pmoles/100nl vehicle) or vehicle directed at the BNST [using a 33 gauge 
injector (Plastics One)] 30 min prior to receiving i.v. infusions of 0.5 M NaLac. An SI test 
was conducted immediately following the lactate challenge.
Measuring ORX-A in the cerebrospinal fluid of subjects with and without panic anxiety
Subjects (n=53) who presented in acute suicidal crisis were systematically assessed for 
psychiatric symptoms utilizing the CPRS. A threshold cut off at 1.5 on item 3 (panic, inner 
tension) on that scale was used to define a subject as having significant panic symptoms. 
Lumbar punctures were performed to collect CSF33, and samples stored at −80°C. CSF-
ORX-A levels were measured in duplicate using an 125I radioimmunoassay (Phoenix 
Pharmaceuticals). All subjects with substance abuse and traces of medication in the blood 
were excluded from the analysis. This study was approved by the Lund University Medical 
Ethics Committee.
Statistical analyses
All values are expressed as means ± s.e.m. or means ± s.d. as noted. Where indicated, we 
assessed between groups effects using paired or unpaired t-tests for 2 groups and ANOVA's 
with Tukey's HSD post-hoc test for >2 groups. A non-parametric Kruskal-Wallis ANOVA 
test was used for the open field test due to unequal variance (see results) and for clinical 
data. Within groups effects were assessed using a one-tailed Dunnet's test. The alpha level 
was set at < 0.05 in all cases. (Excel 2007, SPSS 16.0 and Systat 5.0 were used to analyze 
data and SigmaPlot 8.0 and CorelDraw 12.0 was used to plot and illustrate data).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
a) Left: Mean no. of c-Fos/ORX-A-ir neurons in the DMH/PeF and LH of rats challenged 
with either sodium lactate (Lac) or saline (Sal). Bars with black lines = no. of c-Fos/ORX-A-
ir neurons; grey, open bars = total no. of ORX-A-ir neurons. Middle: photomicrographs 
representing c-Fos (blue nuclei) and ORX-A-ir neurons (brown cytoplasmic) in the DMH 
with arrows indicating c-Fos/ORX-A-ir neurons. Scale bars = 50 μm, 125 μm for inset. 
Right: Mean no. of c-Fos/ORX-A-ir neurons in the DMH/PeF correlated with changes in 
social interaction (SI). Effects of prior (48h) injections of small interfering (si) RNA 
targeting prepro-orexin mRNA (siORX), but not control siRNA (siCON), into the DMH/PeF 
of panic-prone rats (l-AG treated) on: b) anxiety-like responses (SI duration, * and † indicate 
p<0.05); c) general locomotor activity; d) heart rate (HR); and e) mean arterial blood 
pressure (MAP). For locomotor and cardiovascular data, *, a, and b indicate p<0.05. f) 
Coronal illustration of unilateral l-AG infusions, bilateral siORX or siCON injections, and 
micropunches taken for mRNA assays; g) Effects of siORX into the DMH/PeF of control 
rats on concentrations of local prepro-ORX (ppORX) mRNA in the combined DMH/LH. 
Effects of bilateral injections of siORX or siCON into the DMH/PeF of panic-prone rats 
challenged with Lac or saline on local h) ppORX, i) pro-dynorphin (pDyn) and j) 
proopiomelanocortin (POMC) mRNA. The last bar in figures 1h-j represents the 
concentration of mRNA in the DMH/LH of untreated homecage control rats. For Fig. 1h-j, * 
and # respectively indicate p<0.05 compared to siCON/Sal or siORX+Sal groups. All 
mRNA levels are expressed relative to beta-actin mRNA levels. Bars and lines represent 
means; error bars represent SEM. Abbreviations: contra, contralateral; DA, dorsal 
hypothalamic area; DMH, dorsomedial hypothalamus; ipsi, ipsilateral; LH, lateral 
hypothalamus.
Johnson et al. Page 9
Nat Med. Author manuscript; available in PMC 2010 July 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 2. 
a) Effect of systemically injecting the ORX1 receptor antagonist (SB334867) or 
benzodiazepine (alprazolam) into panic-prone rats prior to NaLac challenges on a) anxiety-
like responses [social interaction (SI)], general locomotor activity, heart rate (HR), and mean 
arterial blood pressure (MAP). For anxiety tests in Fig. 2a, and 2b, * and + indicate 
significant differences between groups using a Tukey's HSD tests with p<0.05. For 
locomotor and cardiovascular data in Fig 2a–c * indicates significantly different from 
baseline using a Dunnet's test and † indicate significant differences between groups using a 
Tukey's HSD or paired t-test with p<0.05. b) Effects of systemically injecting SB334867 
into panic-prone rats prior to NaLac challenges on anxiety-like responses (decreased time 
spent in center of open field), general locomotor activity, HR, and MAP. c) Effects of 
systemically injecting a 2nd ORX1 receptor antagonist (SB408124) into panic-prone rats 
prior to NaLac on SI duration, general locomotor activity, HR and MAP. See Suppl. Fig. 
2a–2c for respective probe-placement verification. Bars and lines in graphs represent the 
mean, and error bars represent the standard error of the mean.
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Figure 3. 
Assessment of defensive shock associated behaviors in panic-prone rats (l-AG treated) 
challenged with isotonic saline (Sal) or hypertonic sodium lactate with a prior 
intraperitoneal injection of either a vehicle (Veh) or an orexin 1 receptor antagonist 
(30mg/kg SB334868: SB33). Duration of: a) freezing, near probe (see gray shaded area in 
defensive shock cage illustration in inset in figure 3a) grooming, burying; and b) number of 
line crossings (see dashed line in illustration inset in figure 3a). * indicates significant 
differences between all other groups using a Tukey's HSD tests with p<0.05. c) Effects of 
unilateral injections of the ORX1 receptor antagonist SB334867 (300pmoles/100nl) into the 
bed nucleus of the stria terminalis (BNST) of l-AG treated rats, prior to a sodium lactate 
challenge, on the duration of SI (compared to SI duration following vehicle injection). Bars 
in graphs represent the mean, and error bars represent the standard error of the mean. * 
indicates significant differences between groups using a paired t-test with p<0.05. See 
Supplemental Figure 1d for l-AG infusion placement verification in DMH/PeF and 
injections sites into the BNST.
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Figure 4. 
Results of the human translational study: bar graph illustrates ORX concentrations in 
cerebrospinal fluid (CSF: obtained by lumbar puncture) samples from all subjects, which 
were assayed using a radioimmunoassay33. A cohort of subjects who presented with acute 
suicidal behavior was systematically assessed for psychiatric symptoms utilizing the 
comprehensive psychopathological rating scale (CPRS), where item 3 (inner tension) 
assesses panic anxiety. A threshold cut off at 1.5 on this item was used to define a subject as 
having significant panic symptoms. All subjects with substance abuse and traces of 
antidepressive, neuroleptic or anxiolytic medication in the blood were excluded from the 
analysis. A total of 53 medication-free subjects were included comprising three groups: 
subjects with panic anxiety without major depressive disorder (MDD) (n=12); subjects with 
both panic and co-morbid MDD (n=13); and subjects without panic, without MDD (n=28). * 
indicates significant differences from other groups, using Kruskall Wallis ANOVA 
(P=0.004); and two-tailed Mann-Whitney U-test (subjects with panic and MDD, p= 0.002; 
subjects without panic, p=0.01). Bars in graph represent the mean, and error bars represent 
standard deviation of the mean. Supplemental Table 2 describes details of subject 
characteristics. Age and gender did not have any impact on CSF ORX levels (Pearsons R 
and Mann-Whitney U-tests, P>0.1).
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